Plasminogen activator inhibitor (PAI)-1 is the main inhibitor of the fibrinolytic system and is known to play an essential role in tissue remodeling. Recent evidence indicates that chronic asthma may lead to tissue remodeling such as subepithelial fibrosis and extracellular matrix (ECM) deposition in the airways. However, the role of PAI-1 in asthma is unknown. Recently the mast cell (MC), which plays a major role in asthma, was found as a novel source of PAI-1, and a large number of MCs expressing PAI-1 are infiltrated in the airways of patients with severe asthma. Furthermore, PAI-1-deficient mice show reduced ECM deposition in the airways of a murine model of chronic asthma by inhibiting MMP-9 activity and fibrinolysis. In a human study, the 4G allele frequency was significantly higher in the asthmatic patients than in the control group. In view of the findings that the 4G allele is associated with elevated plasma PAI-1 level, elevated PAI-1 level in the lung may contribute to the development of asthma. In summary, PAI-1 may play an important role in the pathogenesis of asthma and further studies evaluating the mechanisms of PAI-1 action may lead to the development of a novel therapeutic target for the treatment and prevention of asthma.
RocheWRWilliamsJHBeaslyRHolgateST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet1:520–524, 1989.
2.
AikawaTShimuraSSasakiHEbinaMTakashimaT. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest101:916–921, 1992.
3.
HeardBEHossainS. Hyperplasia of bronchial muscle in asthma. J Pathol110:319–331, 1973.
4.
EbinaMTakahashiTChibaTMotomiyaM. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma: a 3-D morphometric study. Am Rev Respir Dis48:720–726, 1973.
5.
EliasJAZhuZChuppGHomerRJ. Airway remodeling in asthma. J Clin Invest104:1001–1006, 1999.
6.
BusseWEliasJSheppardDBanks-SchlegelS. Airway remodeling and repair. Am J Respir Crit Care Med160:1035–1042, 1999.
7.
LangePParnerJVestboJSchnohrPJensenGN. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med339:1194–1200, 1998.
8.
LaitinenLALaitinenAHaahtelaT. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol90:32–42, 1992.
9.
VanackerNJPalmansEKipsJCPauwelsRA. Fluticasone inhibits but does not reverse allergen-induced structural airway changes. Am J Respir Crit Care Med163:674–679, 2000.
10.
CollenD. The plasminogen (fibrinolytic) system. Thromb Haemost82:259–270, 1999.
11.
EitzmanDTMcCoyRDZhengXFayWPShenTGinsburgDSimonRH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest97:232–237, 1996.
12.
EddyAA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol283: F209–F220, 2002.
13.
OhCKAriueBAlbanRFShawBChoSH. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun294:1055–1060, 2002.
14.
ChoSHHallIPWheatleyADewarJAbrahaDDel MundoJLeeHOhCK. Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J Allergy Clin Immunol108:212–214, 2001.
15.
BuckovaDIzakovicova HollaLVachaJ. Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy57:446–448, 2002.
16.
National Heart, Lung, and Blood Institute/World Health Organization.Global strategy for asthma management and prevention. NHLBI/WHO workshop report, March 1993. Bethesda: National Institutes of Health, National Heart, Lung, and Blood Institute Publication No. 95–3659; January1995.
17.
AzzawiMBradleyBJefferyPKFrewAJWardlawAJKnowlesGAssoufiBCollinsJVDurhamSKayAB. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis142:1407–1413, 1990.
18.
WalkerCBodeEBoerLHanselTTBlaserKVirchowJCJr.. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis146:109–115, 1992.
19.
RobinsonDSHamidQYingSTsicopoulosABarkansJBentleyAMCorriganCDurhamSRKayAB. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med326:298–304, 1992.
20.
HolgateS. Mediators and cytokine mechanisms in asthma. Thorax48:103–109, 1993.
21.
KayAB. Asthma and inflammation. J Allergy Clin Immunol87:893–910, 1991.
22.
BousquetJChanezPVignolaAMLacosteJYMichelFB. Eosinophilic inflammation in asthma. Am J Respir Crit Care Med150: S33–S338, 1994.
23.
SurSAdolphsonCRGleichGJ. Eosinophils: biochemical and cellular aspects. In: MiddletonEJr.ReedCEEllisEF, eds. Allergy Principles and Practice (4th ed.). St. Louis: Mosby, pp 169–200, 1993.
24.
GalliSJWershilBKCostaJJTsaiM. For better or for worse: does stem cell factor importantly regulate mast cell function in pulmonary physiology and pathology?Am J Respir Cell Mol Biol11: 644–645, 1994.
25.
WilliamsCMGalliSJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med192:455–462, 2000.
26.
MasudaTTanakaHKomaiMNagaoKIshizakiMKajiwaraDNagaiH. Mast cells play a partial role in allergen-induced subepithelial fibrosis in a murine model of allergic asthma. Clin Exp Allergy33:705–13, 2003.
27.
WassermanSI. Biochemical mediators of allergic reactions. In: PattersonRGrammerLCGreenbergerPA, Eds. Allergic Diseases: diagnosis and management (5th ed.). New York: JB Lippincott, pp 49–56, 1997.
28.
SchwartzLBIraniAARollerKCastellsMCSchechterNM. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol138:2611–2615, 1987.
29.
LongphreMZhangLYPaquetteNKleebergerSR. PAF induced airways hyperreactivity is modulated by mast cells in mice. Am J Respir Cell Mol Biol14:461–469, 1996.
30.
MurakamiMAustinKFArmJP. The immediate phase of c-kit ligand stimulation of mouse bone marrow-derived mast cells elicits rapid leukotriene C4 generation through post-translational activation of cytosolic phospholipase A2 and 5-lipoxygenase. J Exp Med182:197–206, 1995.
31.
CasaleTBWoodDRichersonHBZehrBZavalaDHunninghakeGW. Direct evidence of a role for mast cells in the pathogenesis of antigen induced bronchoconstriction. J Clin Invest80:1507–1511, 1987.
32.
O'sullivanSDahlenBDahenS-EKumlinM. Increased urinary excretion of the prostaglandin D2 metabolites 9α, 11ß-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol98:421–432, 1996.
33.
GoetzlEJ. Oxygenation products of arachinonic acid as mediators of hypersensitivity and inflammation. Med Clin North Am65:809–828, 1981.
34.
AustenKF. From slow reacting substance of anaphylaxis to leukotriene C4 synthase. Int Arch Allergy Immunol107:19–24, 1995.
35.
ArmJPLeeTH. Sulphidopeptide leukotrienes in asthma. Clin Sci84:501–510, 1993.
36.
CowburnASSladekKSojaJAdamekLNizankowskaESzezeklikALamBKPenroseJFAustenFKHolgateSTSampsonAP. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest101:834–846, 1998.
37.
HolgateSTBraddingPSampsonAP. Leukotriene antagonists and synthesis inhibitors: new direction in asthma therapy. J Allergy Clin Immunol98:1–13, 1996.
38.
OkadaSKitaHGeorgeTJGleichGJLeifermanKM. Transmigration of eosinophils through basement membrane components in vitro: synergistic effect of PAF and eosinophil active cytokines. Am J Respir Cell Mol Biol16:455–463, 1997.
39.
StafforiniDMSatohKAtkinsonDLTjoelkerLWEberhardtCYoshidaHImaizumiTTakamatsuSZimmermanGAMcIntyreTMGrayPWPrescottSM. Platelet activating factor acetylhydrolase deficiency: a missense mutation in the active site of an antiinflammatory phospholipase. J Clin Invest97:2784–2791, 1996.
40.
HozawaSHorutaYIshiokaSYamakidoM. Effects of a PAF antagonist Y24180 on bronchial responsiveness in patients with asthma. Am J Respir Crit Care Med152:1198–1202, 1995.
41.
PlautMPierceJHWatsonCJHanley-HydeJNordanRPPaulWE. Mast cell lines produce lymphokines in response to cross-linkage of Fee RI or calcium ionophore. Nature339:64–67, 1989.
42.
Wodnar-FilipowiczAHeusserCHMoroniC. Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature339:150–152, 1989.
43.
BurdPRRogersHWGordonJRMartinCAJayaramanSWilsonSDDvorakAMGalliSJDorfME. Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med179:245–257, 1989.
44.
GordonJRGalliSJ. Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature346: 274–276, 1990.
45.
MalaviyaRIkedaTRossEAbrahamSN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature381:77–80, 1996.
46.
EchtenacherBMannelDNHultnerL. Critical protective role of mast cells in a model of acute septic peritonitis. Nature381:75–77, 1996.
47.
GordonJRGalliSJ. Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-α)/cachectin by mouse mast cells stimulated via the FcRI: a mechanism for the sustained action of mast cell-derived TNF-α during IgE-dependent biological responses. J Exp Med174:103–107, 1991.
48.
BraddingPRobertsJABrittenKMMontefortSDjukanovicRMuellerRHeusserCHHowarthPHHolgateST. Interleukin-4, −5, −6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cells as a source of these cytokines. Am J Respir Cell Mol Biol10:471–480, 1994.
49.
MollerALippertULessmannDKoldeGHamannKWelkerPSchadendorfDRosenbachTLugerTCzarnetzkiBM. Human mast cells produce IL-8. J Immunol151:3261–3266, 1993.
50.
NilssonGSvenssonVNilssonK. Constitutive and inducible cytokine mRNA expression in the human mast cell line HMC-1. Scand J Immunol42:76–81, 1995.
51.
RumsaengVVliagoftisHOhCKMetcalfeDD. Lymphotactin gene expression in mast cells following Fc(epsilon) receptor I aggregation: modulation by TGF-beta, IL-4, dexamethasone, and cyclosporin A. J Immunol158:1353–1360, 1997.
52.
OhCKMetcalfeDD. Transcriptional regulation of the TCA3 gene in mast cells after Fc epsilon RI cross-linking. J Immunol153: 325–332, 1994.
53.
OhCKMetcalfeDD. Activated lymphocytes induce promoter activity of the TCA3 gene in mast cells following cell-to-cell contact. Biochem Biophys Res Commun221:510–514, 1996.
54.
OhCKNeurathMChoJJSemereTMetcalfeDD. Two different negative regulatory elements control the transcription of T-cell activation gene 3 in activated mast cells. Biochem J323:511–519, 1997.
55.
GordonJRGalliSJ. Promotion of mouse fibroblast collagen gene expression by mast cells stimulated via the FcRI: role for mast cell-derived transforming growth factor and tumor necrosis factor. J Exp Med180:2027–2037, 1994.
56.
SakaiKRenSSchwartzLB. A novel heparin-dependent processing pathway for human tryptase. J Clin Invest97:988–995, 1996.
57.
TarnEKCaugheyGH. Degradation of neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol3:27–32, 1992.
58.
CaugheyGH. Mast cell tryptase: hoisted by its own petard?J Clin Invest97:895–896, 1996.
59.
RuossSJHartmannTCaugheyGH. Mast cell tryptase is mitogen for cultured fibroblasts. J Clin Invest88:493–499, 1991.
60.
BrownJKTylerCLJonesCARuossSJHartmannTCaugheyGH. Tryptase, the dominant secretory granular protein in human mast cell, is a potent mitogen for cultured dog tracheal smooth muscle cells. Am J Respir Cell Mol Biol13:227–236, 1995.
61.
ChettaAForesiADel DonnoMConsigliGFBertorelliGPesciABarbeeRAOlivieriD. Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. Am J Respir Crit Care Med153:910–917, 1996.
62.
FangKCWoltersPJSteinhoffMBidgolABlountJLCaugheyGH. Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. J Immunol162:5528–5535, 1999.
63.
KanbeNTanakaAKanbeMItakuraAKurosawaMMatsudaH. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol29:2645–2649, 1999.
64.
FrankBTRossallJCCaugheyGHFangKC. Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase. J Immunol. 166:2783–2792, 2001.
65.
KimHSTsaiPBOhCK. The genetics of asthma. Curr Opin Pulm Med4:46–48, 1998.
66.
SchenaMShalonDDavisRWBrownPO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science270:467–470, 1995.
67.
ShalonDSmithSBrownPO. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res6:639–645, 1996.
68.
ChoJJVliagoftisHRumsaengVMetcalfeDDOhCK. Identification and categorization of inducible mast cell genes in a subtraction library. Biochem Biophys Res Commun242:226–230, 1998.
69.
ChoSHChoJJKimISVliagoftisHMetcalfeDDOhCK. Identification and characterization of the inducible murine mast cell gene, imc-415. Biochem Biophys Res Commun252:123–127, 1998.
70.
ChoSHTarnSWDemissie-SandersSFillerSAOhCK. Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol165:3154–3161, 2000.
71.
FowlkesJLWinklerMK. Exploring the interface between metalloproteinase activity and growth factor and cytokine bioavailability. Cytokine Growth Factor Rev13:277–287, 2002.
72.
StemlichtMDWerbZ. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol17:463–516, 2001.
73.
LohiJWilsonCLRobyJDParksWC. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem276:10134–10144, 2001.
74.
YeSHumphriesSHenneyA. Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. Clin Sci94:103–110, 1998.
75.
BrooksPCStrömbladSSandersLCvon SchalschaTLAimesRTStetler-StevensonWGQuigleyJPChereshDA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell85:683–693, 1996.
76.
OkadaYGonojiYNakaKTomitaKNakanishiIIwataKYamashitaKHayakawaT. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem267:21712–21719, 1992.
77.
SuzukiKEnghildJJMorodomiTSalvesenGNagaseH. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry29:10261–10270, 1990.
78.
EeckhoutYVaesG. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J166:21–31, 1977.
79.
HECSWilhelmSMPentlandAPMarnierBLGrantGAEisenAZGoldbergGI. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A86:2632–2636, 1989.
80.
LijnenHRSilenceJVan HoefBCollenD. Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice. Blood91:2045–2053, 1998.
81.
Keski-OjaJLohiJTuuttilaATryggvasonKVartioT. Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res202:471–476, 1992.
82.
OgataYEnghildJJNagaseH. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem267:3581–3584, 1992.
83.
GyetkoMRChenGHMcDonaldRAGoodmanRHuffhagleGBWilkinsonCCFullerJAToewsGB. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest97:1818–1826, 1996.
84.
ShapiroRLDuquetteJGRosesDFNunesIHarrisMNKaminoHWilsonELRifkinDB. Induction of primary cutaneous melanocyte neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res56:3597–3604, 1996.
85.
MayAEKanseSMLundLRGislerRHImhofBAPreissnerKT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med188:1029–1037, 1998.
86.
BajouKNoelAGerardRDMassonVBrunnerNHolst-HansenCSkobeMFusenigNECarmelietPCollenDFoidartJM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med4:923–928, 1998.
87.
CubellisMVAndreasenPRagnoPMayerMDanoKBlasiF. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci U S A86: 4828–4832, 1989.
88.
StephensRWPollanenJTapiovaaraHLeungKCSimPSSalonenEMRonneEBehrendtNDanoKVaheriA. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol108:1987–1995, 1989.
89.
DengGCurridenSAWangSRosenbergSLoskutoffDJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?J Cell Biol134:1563–1571, 1996.
90.
StefanssonSLawrenceDA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature383:441–443, 1996.
91.
KjollerLKanseSMKirkegaardTRodenburgKWRonneEGoodmanSLPreissnerKTOssowskiLAndreasenPA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res232:420–429, 1997.
92.
ChenYQSuMWaliaRRHaoQCovingtonJWVaughanDE. Spl sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem273:8225–8231, 1998.
93.
KeetonMRCurridenSAvan ZonneveldAJLoskutoffDJ. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem266:23048–23052, 1991.
94.
DawsonSJWimanBHamstenAGreenFHumphriesSHenneyAM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem268:10739–10745, 1993.
95.
DennlerSItohSVivienDten DijkePHuetSGauthierJM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J17:3091–3100, 1998.
96.
Van ZonneveldAJCurridenSALoskutoffDJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A85:5525–5529, 1988.
97.
SchleefRRBevilacquaMPSawdeyMGimbroneMAJr.LoskutoffDJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem263:5797–5803, 1988.
98.
MeuldersQHeCJAdidaCPeraldiMNSchleuningWDSraerJDRondeauE. Tumor necrosis factor-α increases antifibrinolytic activity of cultured human mesangial cells. Kidney Int42:327–334, 1992.
99.
DennlerHItohSVivienDDijkePHuetSGauthierJM. Direct binding of Smad3 and Smad4 to critical TGFß-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J17:3091–3100, 1998.
100.
ArtsJGrimbergenJBosmaPJRahmsdorfHJKooistraT. Role of c-Jun and proximal phorbol 12-myristate-13-acetate-(PMA)-responsive elements in the regulation of basal and PMA-stimulated plasminogen-activator inhibitor-1 gene expression in HepG2. Eur J Biochem241:393–402, 1996.
101.
BouchieJLHansenHFeenerEP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vase Biol18:1771–1779, 1998.
102.
EssigMVrtovsnikFNguyenGSraerJDFriedlanderG. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol9:1377–1388, 1998.
103.
GallicchioMHufnaglPWojtaJTippingP. IFN-gamma inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J Immunol157:2610–2617, 1996.
104.
ErikssonPKallinBvan't HooftFMBavenholmPHamstenA. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A92:1851–1855, 1995.
105.
LoskutoffDJQuigleyJP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest106:1441–1443, 2000.
Stetler-StevensonWG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol148:1345–1350, 1996.
108.
EliasJAZhuZChuppGHomerRJ. Airway remodeling in asthma. J Clin Invest104:1001–1006, 1999.
109.
BertozziPAstedtBZenziusLLynchKLeMaireFZapolWChapmanHAJr.. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med322:890–897, 1990.
110.
IdellSJamesKKLevinEGSchwartzBSManchandaNMaunderRJMartinTRMcLartyJFairDS. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest84:695–705, 1989.
111.
BachofenMWeibelER. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis116:589–615, 1977.
112.
ChapmanHAAllenCLStoneOL. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis133:437–443, 1986.
113.
HasdayJDBachwichPRLynchJP3rdSitrinRG. Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res14:261–278, 1988.
114.
ViscardiRMBroderickKSunCCYale-LoehrAJHessamfarATaciakVBurkeKCKoenigKBIdellS. Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome. Am Rev Respir Dis146:492–499, 1992.
115.
IdellSJamesKKCoalsonJJ. Fibrinolytic activity in bronchoalveolar lavage of baboons with diffuse alveolar damage: trends in two forms of lung injury. Crit Care Med20:1431–1440, 1992.
116.
OhCKAriueBAlbanRFShawBChoSH. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun294:1155–1160, 2002.
